Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier.

Eli Lilly (NYSE:LLY) is making a $5.3 billion investment to expand manufacturing for its high-demand anti-obesity drug Zepbound ...

On Monday, Barclays expressed a positive stance on Eli Lilly (NYSE:LLY) stock, maintaining an Overweight rating and a price target ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier. Ricks' payout included $19.7 million in ...

(RTTNews) - Eli Lilly and Co. (LLY ... LLY is currently trading at $905.91 down 0.75 percent or $6.85 on the New York Stock Exchange. The views and opinions expressed herein are the views and ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. Organovo’s stock ...

The Stock Exchange of Thailand has registered six new Depositary Receipts (DR) and Depositary Receipts Express (DRx), referencing shares of Chinese and US companies, which started trading on 11th May ...

Eli Lilly should easily beat ... new indications should make its stock a winner this year. If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way ...